Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

5.0%

1 terminated/withdrawn out of 20 trials

Success Rate

95.0%

+8.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

16%

3 of 19 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1
19(95.0%)
N/A
1(5.0%)
20Total
Phase 1(19)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (20)

Showing 20 of 20 trials
NCT07272135Phase 1Completed

Selective β2-AR Antagonism in Asthma

Role: collaborator

NCT05725005Phase 1Completed

PET Study of Repeated ASN51 in Healthy Volunteers

Role: collaborator

NCT05029401Phase 1Completed

A Study of Oral Ibogaine in Opioid Withdrawal

Role: collaborator

NCT06092788Phase 1Completed

Safety, Pharmacokinetics (PK) and Relative Bioavailability of NTP42:KVA4 as a Solid Oral Dose

Role: collaborator

NCT04443192Phase 1Terminated

A Single Ascending and Repeated Dose Study of Oral ZF874 in Healthy Volunteers and PiXZ Subjects

Role: collaborator

NCT04919863Phase 1Completed

Safety, Tolerability and Pharmacokinetics of NTP42:KVA4

Role: collaborator

NCT02663089Phase 1Completed

A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy Subjects

Role: collaborator

NCT03227796Phase 1Completed

Safety, Tolerability & Pharmacokinetics of LEVI-04 in Healthy Volunteers and Patients With Osteoarthritis Knee Pain

Role: collaborator

NCT04171739Phase 1Completed

Drug-drug Interaction (DDI) Study to Assess Effect of Itraconazole and Rifampicin Upon Olorofim

Role: collaborator

NCT03760848Phase 1Completed

Study of Potential for Drug Interactions Mediated by CYP3A4 Inhibition With Aramchol in Healthy Volunteers

Role: collaborator

NCT03774173Phase 1Completed

Comparison of Aramchol Concentrations With Once or Twice Daily Dosing

Role: collaborator

NCT02688387Phase 1Completed

A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects

Role: collaborator

NCT02647307Phase 1Completed

Study of the Effects of Ethnicity on the Pharmacokinetics, Pharmacodynamics and Safety of DS-1040b

Role: collaborator

NCT02737007Phase 1Completed

A Microdose Study in Healthy Subjects to Describe Intravenous Pharmacokinetics of GSK3191607

Role: collaborator

NCT02428699Not ApplicableCompleted

Study Comparing Blood Levels of Fatty Acids After Consuming Two Forms of Cod Liver Oil

Role: collaborator

NCT02666287Phase 1Completed

GSK961081 Alone and With Fluticasone Furoate (FF), Phase 1 (Ph1), Single Dose Regimen (SD), Repeat Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)

Role: collaborator

NCT02342574Phase 1Completed

F901318 Multiple Ascending Dose Study

Role: collaborator

NCT02680808Phase 1Completed

Evaluation of the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe

Role: collaborator

NCT02518607Phase 1Completed

Safety, Blood Levels and Effects of MGB-BP-3

Role: collaborator

NCT01265914Phase 1Completed

A Study to Evaluate the Safety, Tolerability and Immunogenicity of a Universal Influenza A Vaccine

Role: collaborator

All 20 trials loaded